Skip to: Content
Skip to: Site Navigation
Skip to: Search

December 2, 2008 8:26:26 AM CST

Learn about Newser Points »

Roche Holding

Roche Holding news stories

4 Stories

Roche Makes Genentech Takeover Bid

Swiss pharma bids $43.7B for remaining shares of biotech firm

Wall Street Journal Wall Street Journal Jul 21, 08 6:55 AM CDT
(Newser) - Swiss pharmaceutical company Roche today offered $43.7 billion for the outstanding shares of Genentech, the San Francisco-based biotech firm in which Roche already owns a 55.9% stake, the Wall Street Journal reports. The $89-a-share offer is the latest in a series of big pharma companies, whose new drug development has been lagging, stepping up investment in the more productive biotech sector. More »

More about:  mergers and acquisitions • takeover • Genentech • Roche Holding

Cancer Drug Sales Push Genentech Profits Up 12%

But analysts say Avastin sales slowing

Wall Street Journal Wall Street Journal Apr 11, 08 8:28 AM CDT
(Newser) - Biotech firm Genentech said sales of its blockbuster cancer drug Avastin fueled a first-quarter profit increase of 12%, reports the Wall Street Journal, but the $600 million in sales was below analysts’ projected $622 million, causing some to grumble the drug may have reached a sales plateau. Genentech stock edged up 0.3% in after-hours trading. More »

More about:  FDA • breast cancer • corporate earnings • Genentech • Avastin • Roche Holding

FDA May Add Warnings
to Flu Meds

Hallucinations, other side effects seen with Tamiflu, Relenza

Wall Street Journal Wall Street Journal Nov 23, 07 4:12 PM CST
(Newser) - The FDA may change the labels of flu medications Tamiflu and Relenza to warn of serious side effects such as hallucinations, the Wall Street Journal reports. More than 700 so-called neuropsychiatric events—for example, children trying to "flee" by jumping through windows—and 16 deaths may be related to the drugs. Most reports come from Japan, where the drugs are most popular. More »

More about:  influenza • side effects • Tamiflu • Roche Holding • Relenza

Biotech Giant Slashes Jobs

World biggest biotech cuts 2,600 jobs in $2B restructuring

Wall Street Journal Wall Street Journal Aug 16, 07 1:34 AM CDT
(Newser) - Biotech giant Amgen is slashing spending by $1.9 billion by cutting up to 14 percent of its workforce— 2,600 jobs—and closing some production facilities. The restructuring was triggered by plummeting sales of the company's anemia drug Aranesp. The shake up demonstrates that biotech operations are not immune to the problems that plague traditional drug companies, the Wall Street Journal reports. More »

More about:  biotechnology • Genentech • restructuring • Roche Holding • Cera • Amgen

4 Stories

Today's Most Popular

Loading...

Premium Articles from HighBeam

Find more articles like this

What is Newser?

2008 Codie Finalist

Face it: there's too much news. At Newser a team of editors and writers culls the most important stories from hundreds of U.S. and international sources and reduces them to a headline, picture, and two paragraphs. It's the Newser guarantee: we can take any report or column or video and pack what you need to know into 120 words or less. Newser's short-form aggregation, visual format, and unique information tools help you get more of the kind of news you want, in a quicker and more entertaining way. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »